Barclays Capital on Wednesday upgraded its target price for Catcher Technology Co (可成科技) shares, saying that the metal casings supplier would benefit from expectations that Apple Inc will launch a new version of its iPhone later this year.
Barclays raised its target price on Catcher shares to NT$300 from NT$235, while leaving its “overweight” recommendation on the stock unchanged.
Barclays said it expects Apple’s next-generation smartphone to be launched in the second half of the year and that shipments of the new model will be 35 to 40 percent higher than the previous one.
Catcher is likely to receive between 10 and 20 percent of the casing orders for the new iPhone, which should help lift its earnings in the second half of the year, Barclays said in a report.
Apple currently accounts for about 40 percent of Catcher’s total revenue.
Barclays said that the Taiwanese firm could also benefit from solid demand from its Chinese customers as China remains a fast growing smartphone market.
The report said that due to tight supply, Catcher is likely to increase its production capacity by between 20 and 40 percent in the second half of the year through the addition of 2,000 to 4,000 computer numerical control machines.
Barclays said Catcher is expected to post NT$3.8 in earnings per share for the first quarter, compared with NT$4.62 in earnings per share the previous quarter due to slow-season effects.
However, it projected Catcher’s earnings per share for the whole year to reach NT$20, up from NT$18.38 last year, adding that the figure could continue to rise to NT$26.13 next year.
The anticipated launch of larger iPhone models later this year should benefit Hon Hai Precision Industry Co (鴻海精密) because many smaller iPhones in circulation will likely be replaced, brokerage CLSA Ltd said.
Sales of the new iPhone 6 should be booming once it is launched because 225 million older iPhones will be up for replacement over the iPhone 6’s life cycle from September this year to August next year, CLSA head of technology research Nicolas Baratte said.
Of those 225 million older iPhones, 131 million are 3.5-inch models such as the iPhone 4S, the brokerage said.
“We concur that the launch of larger iPhones [4.7” and 5.5”] should trigger a larger replacement cycle as we believe that many smartphone users favor a display size of 4.5” or larger,” Baratte wrote in a note to clients on April 13.
The high volume of iPhone 6 shipments should increase Hon Hai’s operating margin to 3.1 percent this year from 2.8 percent last year, and company is also expected to more tightly control its working capital and improve its cash flow, he said.
On the back of its improved finances and the upcoming iPhone 6’s product cycle, Baratte upgraded his rating on Hon Hai shares from “underperform” to “outperform,” setting a price target of NT$96.50.
Hon Hai, the main assembler of Apple devices and the world’s largest contract manufacturer of electronic goods, posted consolidated sales of NT$883 billion (US$29.27 billion) in the first quarter of the year, down 33.5 percent from the previous quarter due to the slow season, but up 9.15 percent year-on-year.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and
‘IMPORTANT MILESTONE’: The firm expects to launch the generic of Revlimid in the US after March 2022. It has already launched the product in some European countries Lotus Pharmaceutical Co Ltd (美時化學製藥) has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for lenalidomide, the company said in a statement on Friday. The ANDA approval is for 2.5mg, 5mg, 10mg, 20mg and 25mg capsules of lenalidomide, which is a generic version of blood cancer drug Revlimid developed by Celgene Corp. It is the first product fully developed and manufactured in Lotus’ facilities in Taiwan. Lotus expects to launch the product in the US — based on its patent litigation settlement with Celgene last year — some time after March